Since annual influenza vaccination is recommended for elderly people and individuals with high-risk conditions [1] , many people accumulate successive doses of vaccine. The effect of prior vaccination history on current-season vaccine effectiveness is unclear. In most people, vaccination appears to boost preexisting memory responses against antigenically related strains [2, 3] . Influenza vaccination in prior seasons has demonstrated preventive capacity in some studies [4] [5] [6] , and a meta-analysis did not detect evidence of decreasing protection with influenza vaccination annually repeated for up to 3 seasons [7] . However, vaccine interference may be occurring if protection is lower in individuals who were vaccinated in both the current and previous seasons, compared with those vaccinated in the current season only [8] .
McLean et al described reductions in the effect of current-season vaccination against influenza A(H3N2) and B virus infections in individuals with a history of frequent vaccination [9] . Three successive doses of vaccine containing the 2009 influenza A(H1N1) virus (A[H1N1]pdm09) component have been associated with higher effectiveness than fewer doses [10] , although the study reporting that result did not evaluate the effect of further doses.
A(H1N1)pdm09 first circulated in 2009, giving rise to a pandemic. Apart from the preexisting cross-reactive antibodies found in a proportion of older adults [11] , the rest of the population may be considered to have been virtually naive for this virus by that year. Pandemic monovalent vaccines based on the same initial isolate of influenza A/California/7/2009(nH1N1) virus were used in the 2009-2010 season. This same strain of A(H1N1)pdm09 became part of the trivalent and quadrivalent influenza vaccines in the following seasons (2010-2011 to 2016-2017) , given that mutations detected in the circulating viruses seemed to maintain the antigenic properties of the virus [12, 13] , although decreased binding of human antibodies has been also described [14, 15] . A(H1N1)pdm09 has circulated worldwide in various seasons during these years [16] . This situation provides a unique opportunity to evaluate the effect of repeated vaccinations under conditions of the same vaccine composition and of few changes in the circulating viruses. Such an investigation requires the existence of cohorts in which influenza cases are confirmed, as well as good vaccination registers covering the study population [17] .
The aim of this study was to evaluate the independent and combined effectiveness of the influenza vaccines administered in the current and prior seasons in preventing laboratory-confirmed influenza A(H1N1)pdm09 in Navarra, Spain, from influenza season 2010-2011 to 2015-2016. We also estimated the incremental benefit of the current-season vaccination according to prior vaccination status.
METHODS

Study Population
This study was performed in the region of Navarra, northern Spain, where annual vaccine effectiveness studies have been conducted on a population-based scheme since 2009-2010 [18] [19] [20] [21] [22] [23] . The Regional Health Service provides health care, free at the point of service, to 97% of the Navarra population. The monovalent A(H1N1)pdm09 adjuvanted vaccine was offered to people with major risk conditions in 2009, and the trivalent inactivated vaccine was annually recommended and offered free of charge to people aged ≥60 years and to those with risk factors or major chronic conditions. Other people may also be vaccinated if they pay for the vaccine.
Influenza surveillance was based on automatic reporting of cases of medically attended influenza-like illness (ILI) from all primary healthcare centers and hospitals. ILI was considered to be the sudden onset of any general symptom (fever or feverishness, malaise, headache, or myalgia), in addition to any respiratory symptom (cough, sore throat, or shortness of breath). A sentinel network composed of a representative sample of primary healthcare physicians, covering 16% of the population, was asked to collect swab specimens from 2 sites, the nasopharynx and the pharynx, after obtaining verbal informed consent, from all of their patients with a diagnosis of ILI whose symptoms had begun <5 days previously. The protocol for influenza cases in hospitals establishes early detection and nasopharyngeal and pharyngeal swabbing at admission of all hospitalized patients with ILI. Swabs were analyzed by real-time reverse transcription-polymerase chain reaction (RT-PCR). Strains selected among culture-positive samples with representation of each week and virus type/subtype were sent to the National Influenza Center-Madrid laboratory for genetic characterization by sequencing the HA1 coding portion of the hemagglutinin gene.
Study Design and Statistical Analysis
We carried out a test-negative case-control study nested in the population cohort with continuous residency in the region since 2009 and covered by the Navarra Health Service. Healthcare workers, persons living in nursing homes, and children <6 months of age were excluded. All information relating to each patient was linked using a unique identification number. The Navarra Ethical Committee for Medical Research approved the study protocol.
The cases were medically attended patients with ILI in primary healthcare settings or hospitals in whom A(H1N1)pdm09 infection was confirmed by RT-PCR, and the controls were medically attended patients with ILI in the same respective settings who tested negative for any influenza virus. The study included only the seasons with >20 cases of A(H1N1)pdm09 infection and the consecutive months in which this virus was detected.
For both cases and controls, the influenza vaccination status in the current season and vaccination history with A/ California/7/2009(H1N1)pdm09-like strain was obtained from the regional vaccination register [17] . Patients were considered vaccinated during the current season if they had received seasonal vaccine ≥14 days prior to illness onset.
Percentages were compared by the χ 2 test. Logistic regression was used to calculate the odds ratios (ORs) with their 95% confidence intervals (CIs), adjusting for sex, age group (<5, 5-24, 25-44, 45-64, 65-84 and ≥85 years), major chronic conditions (heart disease, respiratory disease, renal disease, cancer, diabetes mellitus, cirrhosis, dementia, stroke, immunodeficiency, rheumatic disease, and body mass index of ≥40), functional dependence (Barthel index of <40), hospitalization in the previous 12 months, month and season of sample collection, and healthcare setting (primary healthcare and hospital). The vaccine effectiveness was estimated as [(1 -OR) × 100].
Only prior doses of influenza vaccine containing A/ California/7/2009(nH1N1)-like strain were considered, and they included all seasonal vaccine doses received since 2010-2011 and the doses of monovalent A(H1N1)pdm09 vaccine administered in 2009-2010. In children younger than 9 years getting vaccinated for the first time, 2 doses are recommended; in such children, both doses, when registered, were considered. Several models analyzed key points affecting the vaccine effectiveness: current-season and previous-season vaccination, current-season vaccination and the number of vaccine doses in prior seasons, and the time since the last influenza vaccine was received.
Two models tested the combined effect of prior-season and current-season vaccination. The first model included all combinations of vaccine exposure in the current and the immediately previous season: vaccinated in both the current and previous season, vaccinated in the current season only, vaccinated in the previous season only, and not vaccinated in either the current or previous season (reference category).
The second model included exposure variables for all combinations of the current-season vaccination and vaccination history against A(H1N1)pdm09 virus: current-season vaccination and >2 prior doses, current-season vaccination and 1-2 prior doses, current-season vaccination and no prior doses, no current-season vaccination and >2 prior doses, no current-season vaccination and 1-2 prior doses, and no current-season vaccination and no prior doses (reference group). To answer specific questions, variants of this model were made by adding a new variable for the 2009 monovalent A(H1N1)pdm09 vaccination or using the category with the highest effect as the reference. Separate analyses were done by healthcare setting, age group, and season.
From the point of view of individuals who are deciding whether to get vaccinated in the current season, the effect of the current vaccination was evaluated separately within each category of prior vaccination status.
To reduce the difference in opportunities for prior vaccination in individuals included in the study, sensitivity analyses were done that excluded children younger than 9 years and limited the study period to the 2013-2014 season onward. Table 1) .
RESULTS
Characteristics of Cases and Controls
A total of 1278 cases and 2343 controls were included in the analysis. A smaller proportion of cases than controls were aged <5 years (4% vs 13%) or ≥65 years (17% vs 35%), had major chronic conditions (40% vs 52%), and had been hospitalized in the previous 12 months (13% vs 23%). Cases were less frequently recruited in hospital than controls (35% vs 63%). Influenza vaccination in current and prior seasons was less frequent in cases than controls (Table 1) .
Effect of Current and Previous Vaccination
In the seasons included in the study, the adjusted effectiveness of current vaccination against influenza A(H1N1)pdm09 regardless of previous vaccination presented minor variations, ranging from 54% in 2010-2011 to 42% in 2013-2014 and 2015-2016. The models including previous and current vaccination status showed, in general, moderate effectiveness for vaccination in both seasons and for only current vaccination and no significant effect of only previous-season vaccination. The only exception was the 2010-2011 season, in which the previous-season vaccination with 2009 monovalent A(H1N1)pdm09 vaccine maintained a considerable effectiveness (67%; 95% CI, 9%-88%; Table 2 ).
In the pooled analysis of the 4 study periods, the average effectiveness of current-season vaccination was 46% (95% CI, 32%-57%). The model including previous and current vaccination status showed moderate protection for only current vaccination (46%; 95% CI, 23%-62%), only previous vaccination (36%; 95% CI, -1%-59%), and vaccination in both seasons (50%; 95% CI, 34%-61%). As compared to individuals never vaccinated against influenza A(H1N1)pdm09, the vaccine effectiveness in preventing influenza A(H1N1)pdm09 progressively decreased with the number of years since the last dose, from 49% for vaccination in the current season to 36%, 21%, and 5% for the last vaccination 1, 2, and >2 years before, respectively (Table 3) .
Effect of Current-Season Vaccination and of Vaccination History for A(H1N1)pdm09
As compared to individuals never vaccinated against A(H1N1) pdm09, the highest preventive effect was observed in those vaccinated in the current season who had received 1-2 prior doses of vaccine (66%; 95% CI, 49%-78%). The effectiveness was not statistically lower in those vaccinated only in the current season (52%; 95% CI, 28%-68%; P = .217) or in individuals without current vaccination and >2 prior doses (47%; 95% CI, 2%-71%; P = .210). However, the level of protection was lower in individuals vaccinated in the current season after >2 prior doses (38%; 95% CI, 16%-54%; P = .009) and in those currently unvaccinated with 1-2 prior doses (10%; 95% CI, -29%-37%; P < .001; Table 3 ). The first vaccination with 2009 monovalent A(H1N1)pdm09 adjuvanted vaccine was added to the previous model and showed some supplementary protective effect (24%; 95% CI, -6%-45%) but was not statistically significant as compared to first vaccination with seasonal nonadjuvanted vaccine (Supplementary Table 2 ). The results were similar and the Tables 3 and 4 ). The separate analyses for patients in primary healthcare settings and hospitalized patients were broadly consistent with the results previously presented, although some differences were seen. A history of >2 prior doses of A(H1N1)pdm09-containing vaccine seemed to be associated with better protection against hospitalized influenza cases than ambulatory influenza cases, both for persons not vaccinated in the current season (50% vs 14%) and for those who were vaccinated in the current season (41% vs 31%; Figure 1 ). The effectiveness associated with vaccination in the current or prior seasons seemed to be higher in patients younger than <65 years as compared to elderly individuals (Table 4) .
Effect of Current-Season Vaccination, Stratified by Prior Vaccination Status
Among individuals without prior vaccination, current-season vaccination was 51% effective in preventing medically attended influenza (95% CI, 25%-68%). In those with 1-2 prior doses of A(H1N1)pdm09-containing vaccine, current vaccination improved the preventive effect by 64% (95% CI, 37%-80%). In individuals with >2 prior doses, current-season vaccination did not modify significantly the risk of medically attended influenza (-13%; 95% CI, -114%-40%). The same analysis stratified by hospitalized and ambulatory patients provided consistent results (Table 5) .
DISCUSSION
The present study analyzed a population-based cohort linked to a consolidated vaccination register to evaluate the effectiveness of repeated vaccination containing inactivated A(H1N1)pdm09 in preventing A(H1N1)pdm09 infections between the 2010-2011 and 2015-2016 seasons. This evaluation has special characteristics given that most people may be considered virtually naive to this virus before the first vaccine dose, the A(H1N1) pdm09 component of the vaccine remained unchanged during the study period, and no relevant drifts were detected in circulating A(H1N1)pdm09 strains. Therefore, caution should be taken in generalizing these results to other contexts.
The current-season vaccination conferred the highest preventive effect against A(H1N1)pdm09 infection, and the protection progressively decreased during the years since the last vaccination, suggesting that a recent vaccine dose is necessary to achieve successful immune protection.
In the 2010-2011 influenza season, we found some residual protection related to previous monovalent pandemic vaccine, as described by other authors [24] [25] [26] [27] and similar to findings occasionally observed with the seasonal vaccines [9, 28, 29] . The first vaccination with monovalent A(H1N1)pdm09 adjuvanted vaccine, in 2009, seemed to confer a small level of additional protection [10] , which suggests a higher and longer-lasting immune response after first exposure to an adjuvanted vaccine [30] .
Especially remarkable is that >2 prior doses of A(H1N1) pdm09 influenza vaccine without current-season vaccination maintained a considerable protective effect against non-antigenically drifted virus; however, the preventive effect was very low or null after 1-2 prior doses without current-season vaccination. The highest level of protection was achieved by current-season vaccination in individuals with 1-2 prior doses, whereas an interference was detected between >2 prior doses of vaccine with the A(H1N1)pdm09 strain and the current-season vaccination with the same strain, since the effectiveness was significantly lower. An interference of prior and current vaccination has been described by McLean et al in the analyses of influenza A(H3N2) and B viruses [9] . Our results are also consistent with the inverse exposure-response association found between repeated influenza vaccination and hemagglutinin antibodies titers for A(H3N2) [31] . In our case, based on all the findings described above and given what was observed after >2 previous doses with the same virus composition, this phenomenon seems to be due to immune tolerance [32] .
All these findings are reinforced by the fact that the results obtained from hospitalized patients and those in primary healthcare settings were broadly consistent. More than 2 prior doses of A(H1N1)pdm09 vaccine seemed to have a more relevant role in preventing influenza requiring hospitalization than ambulatory cases, which may be due to the poorer immune response among patients who need hospitalization. In older adults, the same vaccination status seemed to have lower effectiveness, which may be due to immunosenescence, as well as to preexisting cross-reactive antibodies in a proportion of them [11] .
The point of view of individuals who are deciding whether to be vaccinated is shown in the analysis of the effect of current vaccination within each category of prior vaccination status (Table 5) . Current-season vaccination provided a benefit to individuals never vaccinated against A(H1N1)pdm09 and to those with 1-2 prior doses of vaccine. In individuals with >2 prior doses of A(H1N1)pdm09 vaccination, current-season vaccine did not show an additional benefit against medically attended A(H1N1)pdm09 infection, but we did not find a significant negative effect. On the other hand, influenza vaccination remains indicated for the prevention of influenza A(H3N2) and B infections. Some limitations should be considered in interpreting the results of this study. Natural immunity due to exposure to A(H1N1)pdm09 was not considered; however, in a previous study we demonstrated that natural exposures were not relevant confounding factors or effect modifiers of influenza vaccine effectiveness [22] .
The sample size in the pooled analysis was considerable, but some subanalyses had limited statistical power; therefore, estimates should be considered with their respective CI. In this study, laboratory-confirmed cases were compared to controls recruited in the same healthcare settings before either patient or physician knew the laboratory result, which reduced selection bias [33] .
The study included individuals with different chances for repeated vaccination, owing to their young age or the recruitment season. Therefore, all analyses were adjusted by age and season to control for potential confounding. Furthermore, we repeated the analysis after excluding children aged <9 years and for the 2013-2014 and 2015-2016 seasons, and the results remained largely unchanged, which rules out relevant selection bias due to this factor. This study included medically attended patients with ILI recruited from the same population in both primary healthcare centers and hospitals. Because the healthcare setting could have acted as a confounding factor, the analyses were adjusted for this variable. The possibility that the healthcare setting might have modified the effect or biased the results was ruled out because of the consistency of the estimates obtained in these 2 patient groups and in the joint analysis. The joint analysis achieved representation of the whole spectrum of patients with medically attended influenza in the population.
In conclusion, influenza vaccinations in current and prior seasons contribute and interact in preventing medically attended influenza. These results suggest that current influenza vaccination or several prior doses are needed to have a high preventive effect against A(H1N1)pdm09 infection, since the protection of prior doses decreased with the years since the last vaccination. Current-season vaccination in individuals with 1-2 prior doses generated the highest level of protection. In individuals without current-season vaccination, >2 prior doses of A(H1N1)pdm09 vaccine maintained a considerable protective effect against non-antigenically drifted virus. Repeated vaccination with the same A(H1N1) pdm09 strain may generate an interference between the effects of prior and current doses. Despite the declining effect of repeated vaccination, current-season vaccination was not inferior to no current vaccination. Therefore, annual influenza vaccination remains the principal preventive option in persons at high risk of developing complications if they contract influenza.
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